AstraZeneca buys oncology-focused Spirogen for up to $440 million
LONDON (Reuters) - British drugmaker AstraZeneca said on Tuesday its MedImmune unit would buy biotech company Spirogen for up to $440 million to bolst...
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/hKDMEedfW7U/story01.htm
No comments:
Post a Comment